Welcome to our dedicated page for Elevance Health news (Ticker: ELV), a resource for investors and traders seeking the latest updates and insights on Elevance Health stock.
Elevance Health, Inc. (ELV) maintains this dedicated news hub for stakeholders tracking developments in health insurance innovation and corporate strategy. Access official press releases, regulatory filings, and operational updates from one of America's largest managers of Blue Cross Blue Shield plans and government-sponsored healthcare programs.
This resource provides investors with timely updates on earnings reports, Medicare Advantage expansions, and strategic partnerships. Analysts will find detailed information about risk management initiatives and market positioning within the competitive healthcare coverage sector.
Key content categories include quarterly financial disclosures, Medicaid program developments, provider network enhancements, and technology investments. All materials are sourced directly from corporate communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Elevance Health's latest announcements. Combine these updates with SEC filings and industry analysis for comprehensive due diligence on this leading health benefits administrator.
Elevance Health (NYSE:ELV) has partnered with the National Association of Community Health Centers (NACHC) to integrate Food as Medicine (FAM) programming into primary care Community Health Centers (CHCs). The initiative expands Elevance's Nourished Well program by training CHC providers to connect Medicaid members at risk for diet-related chronic conditions with personalized nutrition support.
The partnership implements a three-pillar FAM Ecosystem Framework: food access & security through telehealth, clinical integration within primary care workflows, and culturally relevant lifestyle interventions. Additionally, the Elevance Health Foundation will provide a grant to NACHC to assess existing FAM programs, evaluate policies, and develop a scalable CHC model.
The program aims to enhance patient engagement, support chronic disease management, and strengthen preventive health efforts across CHCs serving 34 million patients nationwide. The long-term vision includes developing a Nutrition Center of Excellence as a national model for food-based clinical care.
Elevance Health (NYSE: ELV) has appointed Steve Collis to its Board of Directors, effective August 1, 2025. Collis, who currently serves as Executive Chairman of Cencora (formerly AmerisourceBergen), will join the board's Audit and Finance Committees.
Collis brings significant healthcare leadership experience, having served as President and CEO of Cencora from 2011 to 2024, where he led the company through strategic transformation and global expansion. The appointment aligns with Elevance Health's structured approach to board refreshment and strengthens its governance capabilities in support of the company's strategic objectives.
Elevance Health (NYSE:ELV) and UC Irvine have released results from a groundbreaking clinical trial demonstrating the effectiveness of a digital asthma self-management (DASM) program. The study, involving 901 adult participants across 41 U.S. states, showed significant improvements in asthma symptom control over 12 months.
Participants with uncontrolled asthma using the DASM program, which integrated iPhone and Apple Watch technology, saw their Asthma Control Test scores improve by 4.6 points, compared to 1.8 points in the control group. The program demonstrated benefits across insurance types and ethnicities, though effects were lower among African American participants. Secondary benefits included improved medication adherence and enhanced work productivity.
Elevance Health (NYSE:ELV) reported Q2 2025 results with operating revenue of $49.4 billion, up 14.3% year-over-year. The company revised its FY 2025 guidance, now expecting adjusted EPS of approximately $30.00.
Key metrics show mixed performance: benefit expense ratio increased 260 basis points to 88.9%, while operating expense ratio improved 160 basis points to 10.1%. Medical membership declined by 212,000 to 45.6 million members. The company returned $2.0 billion to shareholders year-to-date through dividends and share repurchases.
The Health Benefits segment generated $41.6 billion in revenue, while Carelon's revenue grew 36% to $18.1 billion. The company declared a Q3 2025 dividend of $1.71 per share.
Elevance Health (NYSE: ELV) has scheduled its second quarter 2025 financial results announcement for July 17, 2025. The company will release results at 6:00 a.m. EDT, followed by a management conference call at 8:30 a.m. EDT to discuss the results and outlook.
Investors can access the conference call using specific dial-in numbers and access codes for both domestic and international participants. A replay will be available from 11:30 a.m. EDT on July 17 until August 15, 2025. Additionally, a live webcast will be accessible through the company's website at www.elevancehealth.com under the "Investors" section.
Elevance Health (NYSE: ELV) reported strong Q1 2025 financial results with operating revenue reaching $48.8 billion, up 15.4% year-over-year. The company achieved an adjusted operating gain of $3.3 billion, representing a 4.1% increase from Q1 2024.
Key financial metrics include diluted EPS of $9.61 and adjusted diluted EPS of $11.97. The company reaffirmed its FY 2025 adjusted diluted EPS guidance of $34.15 to $34.85. During Q1, Elevance returned $1.3 billion to shareholders through share repurchases ($880 million) and dividends ($386 million).
The Health Benefits segment generated $41.4 billion in operating revenue, while Carelon's revenue grew 38% to $16.7 billion. Medical membership increased by 99,000 from year-end 2024, reaching approximately 45.8 million members. The company declared a Q2 2025 dividend of $1.71 per share, payable on June 25, 2025.
Elevance Health (NYSE: ELV) has announced it will release its first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. EDT. The company will host a conference call at 8:30 a.m. EDT the same day to discuss the results and outlook.
Participants can access the call using the following numbers:
- Domestic: 888-947-9963 (Access Code: 3972058)
- International: 312-470-0178 (Access Code: 3972058)
A replay will be available from 11:30 a.m. EDT on April 22 until May 22, 2025, through:
- Domestic: 800-396-1242
- International: 203-369-3272
Elevance Health (NYSE: ELV) reported Q4 2024 operating revenue of $45.0 billion, up 6% year-over-year, and full-year 2024 revenue of $175.2 billion, a 3% increase. The company's Q4 2024 adjusted diluted EPS was $3.84, while full-year adjusted EPS reached $33.04.
The benefit expense ratio increased to 92.4% in Q4, up 320 basis points from the previous year, primarily due to higher Medicaid medical cost trends. The company's operating cash flow was $5.8 billion in 2024. During Q4, Elevance repurchased 4.5 million shares for $1.8 billion and increased its quarterly dividend by 5% to $1.71 per share.
Medical membership decreased by 1.1 million to 45.7 million members, mainly due to Medicaid business attrition. Looking ahead, Elevance projects FY 2025 adjusted EPS to be between $34.15 and $34.85.
Mark Farrah Associates (MFA) analyzed Elevance Health's acquisition of Indiana University Health Plans, completed on December 31, 2024. The analysis reveals that Elevance Health, through its Anthem Blue Cross and Blue Shield subsidiary, is the second-largest health insurer in the US with nearly 3.2 million members in Indiana, four times larger than UnitedHealth Group.
In Indiana's Medicare Advantage (MA) market, Elevance ranks third with 134,006 members. The acquisition of IU Health Plans (ranked fifth) strengthens Elevance's position and puts pressure on second-place Humana. MFA's analysis shows Elevance leads MA market share in Indiana's perimeter counties, while IU Health Plans' presence is concentrated in central regions where UnitedHealth dominates.
Elevance Health (NYSE: ELV) has scheduled its fourth quarter and full year 2024 financial results announcement for January 23, 2025, at 6:00 a.m. EST. The company will host a conference call at 8:30 a.m. EST the same day to discuss the results and future outlook.
Participants can join the call using domestic (888-947-9963) or international (312-470-0178) numbers with access code 3972058. A replay will be available from 11:30 a.m. EST on January 23 until February 21, 2025. The event will also be accessible via live webcast on the company's website under the 'Investors' section.
FAQ
What is the current stock price of Elevance Health (ELV)?
What is the market cap of Elevance Health (ELV)?
